STAT1d
How the ‘amyloid mafia’ took over Alzheimer’s research
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Biogen drops controversial Alzheimer's drug, focuses on other treatments
Biogen will discontinue development of its controversial drug Aduhelm so it can shift efforts to other drugs, including Leqembi, which it developed with Eisai.
Wall Street Journal2y
The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some ...
The TikTok Reversal And The Science Of Illogical Medical Decisions
When smart people make irrational choices, we often assume they are acting out of selfishness, stupidity or stubbornness.
pharmaphorum6d
Aduhelm approval controversy dials up as FDA seeks probe
In another twist to the Aduhelm approval tale, FDA's Janet Woodcock has called for an independent investigation into the relationship between agency staffers and Biogen executives. The acting FDA ...
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
Hosted on MSN1y
Biogen scraps controversial Alzheimer's drug Aduhelm
Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer's in nearly two decades. The pharmaceutical giant is ...
pharmaphorum1mon
ICER revises its view of Aduhelm's price – but not by much
The Institute for Clinical and Economic Review (ICER) was very damning of Biogen's new Alzheimer's disease therapy Aduhelm when it issued its first report on the drug last month, and a swift ...
STAT1mon
Federal watchdog raises some concerns about the FDA’s accelerated approval program
OIG’s report suggests Aduhelm was more of an outlier, as investigators found only three troubling instances out of a sample of 24 accelerated approval drugs. But Ivan Troy, social science ...
Boston College2y
Medicare and prescription drug costs
A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...
The American Journal of Managed Care5d
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...
Seeking Alpha29d
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease. The FDA's ...